Table 3.
Treatment and explant characteristics.
| Variable | AC (N = 82) |
UNOS-DS (N = 229) |
P-value |
|---|---|---|---|
| Type of LRT, n (%) | |||
| First LRT | .34 | ||
| TACE | 45 (55.6) | 143 (63.0) | |
| Y-90 | 29 (35.8) | 66 (29.1) | |
| Ablation | 1 (1.2) | 8 (3.5) | |
| Other | 6 (7.4) | 10 (4.4) | |
| Second LRT | .14 | ||
| TACE | 44 (61.1) | 119 (67.6) | |
| Y-90 | 18 (25.0) | 26 (14.8) | |
| Ablation | 4 (5.6) | 20 (11.4) | |
| Other | 6 (8.3) | 11 (6.3) | |
| Median # LRT until downstaging (DS) (IQR) | 2 (1–3) | 1 (1–2) | <.001 |
| Median mo from 1st LRT to DS (IQR) | 3.9 (2.4–7.8) | 2.4 (1.4–4.6) | <.001 |
| Liver transplant, n (%) | 20 (24.4) | 85 (37.1) | .04 |
| Explant stage, n (% * ) | .89 | ||
| No viable tumor | 2 (10.0) | 14 (16.7) | |
| Within Milan | 10 (50.0) | 38 (45.2) | |
| Outside Milan | 8 (40.0) | 32 (38.1) | |
| Explant microvascular invasion, n (% * ) | 4 (20.0) | 13 (15.5) | .74 |
| HCC recurrence after LT, n (% * ) | 1 (5.0) | 7 (8.2) | >.99 |
Abbreviations: AFP, alpha-fetoprotein; CI, confidence interval; HCC, hepatocellular carcinoma; MELD, Model for End-Stage Liver Disease; NAFLD, nonalcoholic fatty liver disease; LRT, local regional therapy.Abbreviations: AC, all-comers; CTP, Child-Turcotte-Pugh; HCC, hepatocellular carcinoma; IQR, interquartile range; LRT, local regional therapy; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; NAFLD, nonalcoholic fatty liver disease; TACE, transarterial chemoembolization; UNOS-DS, United Network for Organ Sharing-downstaging; Y-90, Yttrium-90.
*
Proportion calculated based on those who received a liver transplant.